Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study observed that different vitiligo lesions display varying repigmentation patterns, which are associated with the extent of depigmentation, sun exposure, lesion stage, and type of therapy used.

This case study reports a man with rapid hair thinning, whitening, and sparse beard, linked to an increased proportion of hair follicles in catagen or telogen phase and peribulbar lymphocytic infiltrate.

This report describes a case of alopecia areata presenting as Marie Antoinette syndrome shortly after Pfizer/BioNTech COVID-19 vaccination, with hair regrowth and partial repigmentation following treatment.

Recent hair loss research shows some progress, especially in understanding male pattern baldness, but effective treatments for many types of hair loss are still lacking.

This review discusses medication-induced gray hair repigmentation, highlighting that certain anti-inflammatory drugs and melanogenesis stimulators can cause diffuse repigmentation, though evidence remains low-quality and these medications are not currently indicated for this purpose.

This case report detailed a 45-year-old woman with diffuse systemic sclerosis who underwent Ayurvedic treatment, leading to reduced depigmentation, new hair growth, and improved well-being over eight weeks. The findings suggest the potential efficacy of a holistic Ayurvedic approach in managing scleroderma symptoms.

In this case study, a 17-month-old girl experienced sudden hair depigmentation during septic shock hospitalization, suggesting systemic stress as a potential trigger for pediatric canities subita associated with diffuse alopecia areata.

This study found that a combined pattern of repigmentation was most commonly observed in vitiligo, with a new 'medium spotted' pattern proposed for areas with few hair follicles.

This case report highlights that a restrictive rice milk diet in a young child led to kwashiorkor with severe malnutrition, skin changes, and developmental regression, which improved with a protein-rich therapeutic diet.

This letter discusses a trichoscopic feature called the color-transition sign for differentiating between alopecia areata incognita and telogen effluvium, and reports no new clinical results.

This study observed that women post-bariatric surgery may be at increased risk for dermatological signs of malnutrition during subsequent pregnancies, highlighting the need for dermatologists to recognize these early symptoms.

This case report describes two acute hair-related manifestations, alopecia areata and Marie Antoinette syndrome, observed in the same patient following COVID-19 infection.

This case study describes a 55-year-old Japanese male with Vogt-Koyanagi-Harada disease who experienced no hair regrowth but did have hair repigmentation after localized steroid injections, highlighting an unusual late-onset poliosis and alopecia, which has not been previously reported.

In this case report, a 30-year-old woman with myasthenia gravis developed vitiligo and alopecia universalis during long-term rituximab therapy. Discontinuation of rituximab and initiation of oral baricitinib led to improvement in skin conditions, underscoring potential immune-related skin effects from rituximab.

In this case report, a 30-year-old woman with myasthenia gravis developed vitiligo and alopecia universalis during long-term rituximab therapy, suggesting a rare association between the drug and these immune-mediated skin conditions, highlighting the potential benefit of early intervention with baricitinib.

This letter to the editor discusses an observed case of hair repigmentation linked with etretinate therapy but reports no new research findings.

This case report describes a unique occurrence of alopecia totalis resulting in pigmented hair growth over superficial scalp veins in an adult female using augmented betamethasone dipropionate ointment.

This case report describes the development of halo naevi, vitiligo, and diffuse alopecia areata in a 33-year-old woman undergoing tocilizumab therapy, suggesting a link between these conditions and cellular and humoral immune factors.

This study suggests that diffuse alopecia areata initially involves an intense inflammatory attack during the anagen phase, progressing through different hair cycle stages with specific shedding patterns.

This letter to the editor discusses a previous clinical and histopathological analysis of four cases of severe diffuse non-scarring hair loss in systemic lupus erythematosus, reporting no new study results.

This case report describes an elderly multiple myeloma patient whose hair repigmentation was associated with lenalidomide use, suggesting hair graying may be reversible.

This case report describes a patient with psoriasis who experienced scalp hair darkening and increased growth during anti–IL-17 therapy.

This excerpt discusses website navigation and access details for JAMA Dermatology and reports no new research findings.

This study describes changes in scalp hair color, including rare instances of repigmentation, following volumetric modulated arc therapy for skin cancer; this potential side effect may warrant discussion during informed consent.

This review reports the first known case of hair repigmentation associated with lamivudine use and examines mechanisms related to drug-induced hair repigmentation, suggesting potential therapeutic strategies for reversing hair graying.

This study found that thymus transplantation in athymic mice resulted in T-cell-driven hair follicle depigmentation and loss, without multiorgan autoimmune disease, highlighting mechanisms of tissue-specific tolerance.

In this case study, an 11-year-old girl with severe alopecia areata experienced complete hair regrowth and unexpected white-to-black hair repigmentation after switching from baricitinib to ritlecitinib, suggesting that prolonged Janus kinase inhibition may aid both hair and pigment restoration in severe pediatric cases.

This report describes a patient experiencing hair repigmentation linked to adalimumab therapy, a TNF inhibitor, a phenomenon not previously associated with this class of drugs.

This review discusses the cutaneous side effects associated with vemurafenib and ipilimumab in metastatic melanoma treatment and emphasizes the importance of dermatologists in managing these skin eruptions; it reports no new clinical results.

This article reviews the process of repigmentation in vitiligo and emphasizes the role of UV light as the most potent stimulus, with no new clinical findings reported.